(NASDAQ: GILD) Gilead Sciences's forecast annual revenue growth rate of 4.79% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.95%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.32%.
Gilead Sciences's revenue in 2026 is $30,988,000,000.On average, 30 Wall Street analysts forecast GILD's revenue for 2026 to be $39,751,612,240,086, with the lowest GILD revenue forecast at $37,997,773,439,890, and the highest GILD revenue forecast at $41,154,435,212,520. On average, 30 Wall Street analysts forecast GILD's revenue for 2027 to be $42,544,854,798,814, with the lowest GILD revenue forecast at $39,152,528,689,524, and the highest GILD revenue forecast at $45,264,917,379,316.
In 2028, GILD is forecast to generate $43,955,119,802,932 in revenue, with the lowest revenue forecast at $39,857,041,022,276 and the highest revenue forecast at $47,926,684,044,960.